nodes	percent_of_prediction	percent_of_DWPC	metapath
Haloperidol—Dyclonine—Raloxifene—breast cancer	0.191	0.688	CrCrCtD
Haloperidol—CYP1A1—breast cancer	0.0612	0.343	CbGaD
Haloperidol—Loperamide—Toremifene—breast cancer	0.0531	0.192	CrCrCtD
Haloperidol—EBP—Raloxifene—breast cancer	0.0527	0.15	CbGbCtD
Haloperidol—CYP2D6—breast cancer	0.0455	0.255	CbGaD
Haloperidol—CYP3A4—breast cancer	0.0391	0.219	CbGaD
Haloperidol—EBP—Tamoxifen—breast cancer	0.0348	0.099	CbGbCtD
Haloperidol—Loperamide—Tamoxifen—breast cancer	0.0333	0.12	CrCrCtD
Haloperidol—ABCB1—breast cancer	0.0325	0.182	CbGaD
Haloperidol—SIGMAR1—Raloxifene—breast cancer	0.0227	0.0644	CbGbCtD
Haloperidol—CBR1—Doxorubicin—breast cancer	0.0213	0.0605	CbGbCtD
Haloperidol—HTR2B—Raloxifene—breast cancer	0.0152	0.0431	CbGbCtD
Haloperidol—SIGMAR1—Tamoxifen—breast cancer	0.015	0.0425	CbGbCtD
Haloperidol—CYP1A1—Toremifene—breast cancer	0.0145	0.0413	CbGbCtD
Haloperidol—UGT1A9—Irinotecan—breast cancer	0.00982	0.0279	CbGbCtD
Haloperidol—CYP1A2—Anastrozole—breast cancer	0.0071	0.0202	CbGbCtD
Haloperidol—CYP1A2—Toremifene—breast cancer	0.00649	0.0185	CbGbCtD
Haloperidol—CYP2C9—Anastrozole—breast cancer	0.0064	0.0182	CbGbCtD
Haloperidol—CYP3A5—Lapatinib—breast cancer	0.00636	0.0181	CbGbCtD
Haloperidol—ABCB1—Toremifene—breast cancer	0.00568	0.0161	CbGbCtD
Haloperidol—CYP1A1—Tamoxifen—breast cancer	0.00531	0.0151	CbGbCtD
Haloperidol—CYP2C19—Lapatinib—breast cancer	0.00513	0.0146	CbGbCtD
Haloperidol—CYP3A4—Exemestane—breast cancer	0.00491	0.0139	CbGbCtD
Haloperidol—CYP2C9—Idarubicin—breast cancer	0.00485	0.0138	CbGbCtD
Haloperidol—CYP2D6—Idarubicin—breast cancer	0.00443	0.0126	CbGbCtD
Haloperidol—CYP3A7—Tamoxifen—breast cancer	0.00425	0.0121	CbGbCtD
Haloperidol—CYP3A7-CYP3A51P—Tamoxifen—breast cancer	0.00425	0.0121	CbGbCtD
Haloperidol—CYP3A4—Letrozole—breast cancer	0.00417	0.0119	CbGbCtD
Haloperidol—ABCB1—Lapatinib—breast cancer	0.00414	0.0118	CbGbCtD
Haloperidol—CYP3A4—Anastrozole—breast cancer	0.00372	0.0106	CbGbCtD
Haloperidol—CYP3A4—Toremifene—breast cancer	0.0034	0.00967	CbGbCtD
Haloperidol—CYP3A7-CYP3A51P—Paclitaxel—breast cancer	0.00331	0.0094	CbGbCtD
Haloperidol—CYP3A7—Paclitaxel—breast cancer	0.00331	0.0094	CbGbCtD
Haloperidol—CYP3A7—Irinotecan—breast cancer	0.00326	0.00927	CbGbCtD
Haloperidol—CYP3A7-CYP3A51P—Irinotecan—breast cancer	0.00326	0.00927	CbGbCtD
Haloperidol—CYP3A5—Tamoxifen—breast cancer	0.00319	0.00906	CbGbCtD
Haloperidol—CYP3A4—Fulvestrant—breast cancer	0.00316	0.00899	CbGbCtD
Haloperidol—CYP3A4—Thiotepa—breast cancer	0.00282	0.00801	CbGbCtD
Haloperidol—CYP2C9—Capecitabine—breast cancer	0.00266	0.00755	CbGbCtD
Haloperidol—CYP3A4—Ixabepilone—breast cancer	0.00258	0.00733	CbGbCtD
Haloperidol—CYP2C19—Tamoxifen—breast cancer	0.00257	0.00731	CbGbCtD
Haloperidol—CYP3A4—Lapatinib—breast cancer	0.00248	0.00705	CbGbCtD
Haloperidol—CYP3A5—Paclitaxel—breast cancer	0.00248	0.00705	CbGbCtD
Haloperidol—CYP3A5—Irinotecan—breast cancer	0.00245	0.00695	CbGbCtD
Haloperidol—CYP3A7-CYP3A51P—Docetaxel—breast cancer	0.00239	0.00679	CbGbCtD
Haloperidol—CYP3A7—Docetaxel—breast cancer	0.00239	0.00679	CbGbCtD
Haloperidol—CYP1A2—Tamoxifen—breast cancer	0.00237	0.00674	CbGbCtD
Haloperidol—ABCB1—Vinorelbine—breast cancer	0.0023	0.00653	CbGbCtD
Haloperidol—CYP2D6—Vinorelbine—breast cancer	0.00217	0.00615	CbGbCtD
Haloperidol—CYP2C9—Tamoxifen—breast cancer	0.00214	0.00607	CbGbCtD
Haloperidol—ABCB1—Tamoxifen—breast cancer	0.00207	0.00589	CbGbCtD
Haloperidol—ABCB1—Mitoxantrone—breast cancer	0.00202	0.00575	CbGbCtD
Haloperidol—CYP2D6—Tamoxifen—breast cancer	0.00195	0.00555	CbGbCtD
Haloperidol—CYP3A4—Raloxifene—breast cancer	0.00188	0.00535	CbGbCtD
Haloperidol—CYP3A5—Docetaxel—breast cancer	0.00179	0.0051	CbGbCtD
Haloperidol—ABCB1—Gemcitabine—breast cancer	0.00179	0.00508	CbGbCtD
Haloperidol—CYP1A2—Fluorouracil—breast cancer	0.00175	0.00497	CbGbCtD
Haloperidol—CYP2C9—Paclitaxel—breast cancer	0.00166	0.00473	CbGbCtD
Haloperidol—ABCB1—Paclitaxel—breast cancer	0.00161	0.00459	CbGbCtD
Haloperidol—ABCB1—Irinotecan—breast cancer	0.00159	0.00453	CbGbCtD
Haloperidol—CYP2C9—Fluorouracil—breast cancer	0.00157	0.00448	CbGbCtD
Haloperidol—ABCB1—Vinblastine—breast cancer	0.00142	0.00402	CbGbCtD
Haloperidol—CYP3A4—Vinorelbine—breast cancer	0.00138	0.00391	CbGbCtD
Haloperidol—CYP2D6—Vinblastine—breast cancer	0.00133	0.00379	CbGbCtD
Haloperidol—CYP3A4—Tamoxifen—breast cancer	0.00124	0.00353	CbGbCtD
Haloperidol—CYP3A4—Mitoxantrone—breast cancer	0.00121	0.00344	CbGbCtD
Haloperidol—ABCB1—Docetaxel—breast cancer	0.00117	0.00332	CbGbCtD
Haloperidol—CYP3A4—Paclitaxel—breast cancer	0.000967	0.00275	CbGbCtD
Haloperidol—CYP3A4—Irinotecan—breast cancer	0.000954	0.00271	CbGbCtD
Haloperidol—ABCB1—Doxorubicin—breast cancer	0.00087	0.00247	CbGbCtD
Haloperidol—CYP3A4—Vinblastine—breast cancer	0.000848	0.00241	CbGbCtD
Haloperidol—ABCB1—Methotrexate—breast cancer	0.000843	0.0024	CbGbCtD
Haloperidol—CYP2D6—Doxorubicin—breast cancer	0.00082	0.00233	CbGbCtD
Haloperidol—Dyclonine—SCN10A—breast cancer	0.000805	0.619	CrCbGaD
Haloperidol—EBP—uterus—breast cancer	0.000794	0.0318	CbGeAlD
Haloperidol—CBR1—mammary gland—breast cancer	0.000786	0.0315	CbGeAlD
Haloperidol—EBP—female reproductive system—breast cancer	0.000714	0.0286	CbGeAlD
Haloperidol—CYP3A4—Docetaxel—breast cancer	0.000699	0.00199	CbGbCtD
Haloperidol—CBR1—nipple—breast cancer	0.00065	0.026	CbGeAlD
Haloperidol—H1F0—mammary gland—breast cancer	0.000644	0.0258	CbGeAlD
Haloperidol—EBP—endocrine gland—breast cancer	0.000604	0.0242	CbGeAlD
Haloperidol—H1F0—nipple—breast cancer	0.000533	0.0213	CbGeAlD
Haloperidol—CBR1—Vincristine—Vinorelbine—breast cancer	0.000529	0.411	CbGdCrCtD
Haloperidol—CYP3A4—Doxorubicin—breast cancer	0.000521	0.00148	CbGbCtD
Haloperidol—SIGMAR1—mammary gland—breast cancer	0.000465	0.0186	CbGeAlD
Haloperidol—H1F0—embryo—breast cancer	0.00044	0.0176	CbGeAlD
Haloperidol—CBR1—Vincristine—Vinblastine—breast cancer	0.000423	0.329	CbGdCrCtD
Haloperidol—CBR1—skin of body—breast cancer	0.000417	0.0167	CbGeAlD
Haloperidol—CBR1—endometrium—breast cancer	0.000393	0.0157	CbGeAlD
Haloperidol—SIGMAR1—nipple—breast cancer	0.000385	0.0154	CbGeAlD
Haloperidol—GRIN2B—endocrine gland—breast cancer	0.000371	0.0149	CbGeAlD
Haloperidol—UGT1A9—endocrine gland—breast cancer	0.000366	0.0146	CbGeAlD
Haloperidol—CBR1—uterus—breast cancer	0.000362	0.0145	CbGeAlD
Haloperidol—CBR1—pituitary gland—breast cancer	0.000355	0.0142	CbGeAlD
Haloperidol—CBR1—adipose tissue—breast cancer	0.000354	0.0142	CbGeAlD
Haloperidol—H1F0—skin of body—breast cancer	0.000341	0.0137	CbGeAlD
Haloperidol—CBR1—female reproductive system—breast cancer	0.000325	0.013	CbGeAlD
Haloperidol—H1F0—endometrium—breast cancer	0.000322	0.0129	CbGeAlD
Haloperidol—CBR1—adrenal gland—breast cancer	0.000317	0.0127	CbGeAlD
Haloperidol—CBR1—bone marrow—breast cancer	0.000307	0.0123	CbGeAlD
Haloperidol—KCNH2—nipple—breast cancer	0.000306	0.0123	CbGeAlD
Haloperidol—CYP3A7—endocrine gland—breast cancer	0.000304	0.0122	CbGeAlD
Haloperidol—CYP2C9—mammary gland—breast cancer	0.000301	0.012	CbGeAlD
Haloperidol—H1F0—uterus—breast cancer	0.000297	0.0119	CbGeAlD
Haloperidol—CBR1—female gonad—breast cancer	0.000296	0.0119	CbGeAlD
Haloperidol—H1F0—pituitary gland—breast cancer	0.000291	0.0117	CbGeAlD
Haloperidol—H1F0—adipose tissue—breast cancer	0.00029	0.0116	CbGeAlD
Haloperidol—CBR1—endocrine gland—breast cancer	0.000275	0.011	CbGeAlD
Haloperidol—H1F0—female reproductive system—breast cancer	0.000267	0.0107	CbGeAlD
Haloperidol—CYP1A2—nipple—breast cancer	0.000262	0.0105	CbGeAlD
Haloperidol—H1F0—adrenal gland—breast cancer	0.00026	0.0104	CbGeAlD
Haloperidol—CYP1A1—nipple—breast cancer	0.000259	0.0104	CbGeAlD
Haloperidol—H1F0—bone marrow—breast cancer	0.000252	0.0101	CbGeAlD
Haloperidol—HTR2B—skin of body—breast cancer	0.000246	0.00984	CbGeAlD
Haloperidol—HRH1—nipple—breast cancer	0.000246	0.00983	CbGeAlD
Haloperidol—H1F0—female gonad—breast cancer	0.000243	0.00971	CbGeAlD
Haloperidol—SIGMAR1—endometrium—breast cancer	0.000232	0.0093	CbGeAlD
Haloperidol—HTR2B—endometrium—breast cancer	0.000232	0.00928	CbGeAlD
Haloperidol—H1F0—endocrine gland—breast cancer	0.000226	0.00903	CbGeAlD
Haloperidol—SIGMAR1—uterus—breast cancer	0.000214	0.00857	CbGeAlD
Haloperidol—HTR2B—uterus—breast cancer	0.000214	0.00855	CbGeAlD
Haloperidol—HTR1B—female reproductive system—breast cancer	0.000213	0.00854	CbGeAlD
Haloperidol—SIGMAR1—pituitary gland—breast cancer	0.00021	0.00842	CbGeAlD
Haloperidol—SIGMAR1—adipose tissue—breast cancer	0.000209	0.00838	CbGeAlD
Haloperidol—HTR2B—adipose tissue—breast cancer	0.000209	0.00837	CbGeAlD
Haloperidol—HTR1D—female reproductive system—breast cancer	0.000206	0.00827	CbGeAlD
Haloperidol—CBR1—Azacitidine—Gemcitabine—breast cancer	0.000199	0.155	CbGdCrCtD
Haloperidol—HTR2B—female reproductive system—breast cancer	0.000192	0.00769	CbGeAlD
Haloperidol—CBR1—lymph node—breast cancer	0.00019	0.00762	CbGeAlD
Haloperidol—SIGMAR1—adrenal gland—breast cancer	0.000188	0.00752	CbGeAlD
Haloperidol—HTR2B—adrenal gland—breast cancer	0.000187	0.0075	CbGeAlD
Haloperidol—KCNH2—endometrium—breast cancer	0.000185	0.0074	CbGeAlD
Haloperidol—SIGMAR1—bone marrow—breast cancer	0.000182	0.00728	CbGeAlD
Haloperidol—HTR1B—endocrine gland—breast cancer	0.00018	0.00722	CbGeAlD
Haloperidol—SIGMAR1—female gonad—breast cancer	0.000175	0.00701	CbGeAlD
Haloperidol—CYP1A1—epithelium—breast cancer	0.000174	0.00697	CbGeAlD
Haloperidol—KCNH2—uterus—breast cancer	0.00017	0.00682	CbGeAlD
Haloperidol—DRD2—pituitary gland—breast cancer	0.00017	0.0068	CbGeAlD
Haloperidol—HTR2A—embryo—breast cancer	0.000169	0.00677	CbGeAlD
Haloperidol—KCNH2—pituitary gland—breast cancer	0.000167	0.0067	CbGeAlD
Haloperidol—CYP1A1—skin of body—breast cancer	0.000166	0.00663	CbGeAlD
Haloperidol—HRH1—epithelium—breast cancer	0.000165	0.00662	CbGeAlD
Haloperidol—H1F0—lymph node—breast cancer	0.000156	0.00624	CbGeAlD
Haloperidol—KCNH2—female reproductive system—breast cancer	0.000153	0.00613	CbGeAlD
Haloperidol—KCNH2—adrenal gland—breast cancer	0.00015	0.00599	CbGeAlD
Haloperidol—HRH1—endometrium—breast cancer	0.000148	0.00593	CbGeAlD
Haloperidol—Moclobemide—CYP2D6—breast cancer	0.000146	0.112	CrCbGaD
Haloperidol—KCNH2—bone marrow—breast cancer	0.000145	0.00579	CbGeAlD
Haloperidol—CYP1A1—uterus—breast cancer	0.000144	0.00576	CbGeAlD
Haloperidol—CYP1A1—adipose tissue—breast cancer	0.000141	0.00564	CbGeAlD
Haloperidol—KCNH2—female gonad—breast cancer	0.000139	0.00558	CbGeAlD
Haloperidol—HTR2A—epithelium—breast cancer	0.000138	0.00553	CbGeAlD
Haloperidol—CYP3A5—adipose tissue—breast cancer	0.000138	0.00551	CbGeAlD
Haloperidol—CYP2C19—endocrine gland—breast cancer	0.000136	0.00544	CbGeAlD
Haloperidol—EBP—Azacitidine—Gemcitabine—breast cancer	0.000136	0.105	CbGdCrCtD
Haloperidol—HRH1—adipose tissue—breast cancer	0.000134	0.00535	CbGeAlD
Haloperidol—DRD2—endocrine gland—breast cancer	0.000132	0.00527	CbGeAlD
Haloperidol—KCNH2—endocrine gland—breast cancer	0.00013	0.00519	CbGeAlD
Haloperidol—CYP1A1—female reproductive system—breast cancer	0.000129	0.00518	CbGeAlD
Haloperidol—CYP2C9—female reproductive system—breast cancer	0.000125	0.00498	CbGeAlD
Haloperidol—HRH1—female reproductive system—breast cancer	0.000123	0.00492	CbGeAlD
Haloperidol—HRH1—adrenal gland—breast cancer	0.00012	0.0048	CbGeAlD
Haloperidol—CYP1A1—female gonad—breast cancer	0.000118	0.00471	CbGeAlD
Haloperidol—CYP3A5—female gonad—breast cancer	0.000115	0.00461	CbGeAlD
Haloperidol—SIGMAR1—lymph node—breast cancer	0.000113	0.00451	CbGeAlD
Haloperidol—HTR2B—lymph node—breast cancer	0.000112	0.0045	CbGeAlD
Haloperidol—HTR2A—pituitary gland—breast cancer	0.000112	0.00449	CbGeAlD
Haloperidol—HRH1—female gonad—breast cancer	0.000112	0.00447	CbGeAlD
Haloperidol—CYP1A2—endocrine gland—breast cancer	0.000111	0.00444	CbGeAlD
Haloperidol—ABCB1—embryo—breast cancer	0.000111	0.00444	CbGeAlD
Haloperidol—Sertindole—CYP2D6—breast cancer	0.00011	0.0849	CrCbGaD
Haloperidol—CYP1A1—endocrine gland—breast cancer	0.00011	0.00438	CbGeAlD
Haloperidol—CYP3A5—endocrine gland—breast cancer	0.000107	0.00429	CbGeAlD
Haloperidol—CYP2C9—endocrine gland—breast cancer	0.000105	0.00422	CbGeAlD
Haloperidol—HRH1—endocrine gland—breast cancer	0.000104	0.00416	CbGeAlD
Haloperidol—HTR2A—female reproductive system—breast cancer	0.000103	0.00411	CbGeAlD
Haloperidol—HTR2A—adrenal gland—breast cancer	0.0001	0.00401	CbGeAlD
Haloperidol—CYP3A4—female reproductive system—breast cancer	9.5e-05	0.0038	CbGeAlD
Haloperidol—Sertindole—CYP3A4—breast cancer	9.47e-05	0.0729	CrCbGaD
Haloperidol—CYP2D6—female reproductive system—breast cancer	9.34e-05	0.00374	CbGeAlD
Haloperidol—ABCB1—epithelium—breast cancer	9.05e-05	0.00362	CbGeAlD
Haloperidol—KCNH2—lymph node—breast cancer	8.96e-05	0.00359	CbGeAlD
Haloperidol—HTR2A—endocrine gland—breast cancer	8.68e-05	0.00347	CbGeAlD
Haloperidol—CYP2D6—female gonad—breast cancer	8.5e-05	0.0034	CbGeAlD
Haloperidol—ABCB1—endometrium—breast cancer	8.11e-05	0.00325	CbGeAlD
Haloperidol—CYP3A4—endocrine gland—breast cancer	8.04e-05	0.00322	CbGeAlD
Haloperidol—CYP2D6—endocrine gland—breast cancer	7.91e-05	0.00317	CbGeAlD
Haloperidol—CYP1A1—lymph node—breast cancer	7.57e-05	0.00303	CbGeAlD
Haloperidol—ABCB1—uterus—breast cancer	7.48e-05	0.00299	CbGeAlD
Haloperidol—ABCB1—pituitary gland—breast cancer	7.34e-05	0.00294	CbGeAlD
Haloperidol—ABCB1—adipose tissue—breast cancer	7.31e-05	0.00293	CbGeAlD
Haloperidol—HRH1—lymph node—breast cancer	7.18e-05	0.00288	CbGeAlD
Haloperidol—ABCB1—female reproductive system—breast cancer	6.72e-05	0.00269	CbGeAlD
Haloperidol—ABCB1—adrenal gland—breast cancer	6.56e-05	0.00263	CbGeAlD
Haloperidol—ABCB1—bone marrow—breast cancer	6.35e-05	0.00254	CbGeAlD
Haloperidol—ABCB1—female gonad—breast cancer	6.12e-05	0.00245	CbGeAlD
Haloperidol—ABCB1—endocrine gland—breast cancer	5.69e-05	0.00228	CbGeAlD
Haloperidol—Loperamide—CYP2D6—breast cancer	5.62e-05	0.0432	CrCbGaD
Haloperidol—Loperamide—CYP3A4—breast cancer	4.82e-05	0.0371	CrCbGaD
Haloperidol—Loperamide—ABCB1—breast cancer	4.01e-05	0.0309	CrCbGaD
Haloperidol—ABCB1—lymph node—breast cancer	3.93e-05	0.00157	CbGeAlD
Haloperidol—Oedema—Docetaxel—breast cancer	2.82e-05	0.000299	CcSEcCtD
Haloperidol—Weight increased—Doxorubicin—breast cancer	2.81e-05	0.000298	CcSEcCtD
Haloperidol—Pruritus—Gemcitabine—breast cancer	2.81e-05	0.000298	CcSEcCtD
Haloperidol—Nausea—Thiotepa—breast cancer	2.8e-05	0.000297	CcSEcCtD
Haloperidol—Urethral disorder—Methotrexate—breast cancer	2.8e-05	0.000297	CcSEcCtD
Haloperidol—Weight decreased—Doxorubicin—breast cancer	2.8e-05	0.000296	CcSEcCtD
Haloperidol—Hyperglycaemia—Doxorubicin—breast cancer	2.79e-05	0.000296	CcSEcCtD
Haloperidol—Diarrhoea—Irinotecan—breast cancer	2.79e-05	0.000295	CcSEcCtD
Haloperidol—Diarrhoea—Mitoxantrone—breast cancer	2.79e-05	0.000295	CcSEcCtD
Haloperidol—Dry mouth—Capecitabine—breast cancer	2.78e-05	0.000295	CcSEcCtD
Haloperidol—Agranulocytosis—Epirubicin—breast cancer	2.78e-05	0.000295	CcSEcCtD
Haloperidol—Nervous system disorder—Docetaxel—breast cancer	2.76e-05	0.000293	CcSEcCtD
Haloperidol—Pruritus—Fluorouracil—breast cancer	2.76e-05	0.000293	CcSEcCtD
Haloperidol—Thrombocytopenia—Docetaxel—breast cancer	2.76e-05	0.000292	CcSEcCtD
Haloperidol—Drowsiness—Doxorubicin—breast cancer	2.76e-05	0.000292	CcSEcCtD
Haloperidol—Visual impairment—Methotrexate—breast cancer	2.76e-05	0.000292	CcSEcCtD
Haloperidol—Confusional state—Capecitabine—breast cancer	2.75e-05	0.000291	CcSEcCtD
Haloperidol—Tachycardia—Docetaxel—breast cancer	2.75e-05	0.000291	CcSEcCtD
Haloperidol—Feeling abnormal—Paclitaxel—breast cancer	2.74e-05	0.00029	CcSEcCtD
Haloperidol—Skin disorder—Docetaxel—breast cancer	2.74e-05	0.00029	CcSEcCtD
Haloperidol—Oedema—Capecitabine—breast cancer	2.73e-05	0.000289	CcSEcCtD
Haloperidol—Diarrhoea—Gemcitabine—breast cancer	2.72e-05	0.000288	CcSEcCtD
Haloperidol—Dizziness—Irinotecan—breast cancer	2.7e-05	0.000286	CcSEcCtD
Haloperidol—Jaundice—Doxorubicin—breast cancer	2.69e-05	0.000285	CcSEcCtD
Haloperidol—Anorexia—Docetaxel—breast cancer	2.69e-05	0.000285	CcSEcCtD
Haloperidol—Nervous system disorder—Capecitabine—breast cancer	2.68e-05	0.000283	CcSEcCtD
Haloperidol—Hepatitis—Epirubicin—breast cancer	2.68e-05	0.000283	CcSEcCtD
Haloperidol—Eye disorder—Methotrexate—breast cancer	2.67e-05	0.000283	CcSEcCtD
Haloperidol—Diarrhoea—Fluorouracil—breast cancer	2.67e-05	0.000283	CcSEcCtD
Haloperidol—Thrombocytopenia—Capecitabine—breast cancer	2.67e-05	0.000283	CcSEcCtD
Haloperidol—Tachycardia—Capecitabine—breast cancer	2.66e-05	0.000282	CcSEcCtD
Haloperidol—Cardiac disorder—Methotrexate—breast cancer	2.65e-05	0.000281	CcSEcCtD
Haloperidol—Skin disorder—Capecitabine—breast cancer	2.65e-05	0.000281	CcSEcCtD
Haloperidol—Urinary tract disorder—Epirubicin—breast cancer	2.64e-05	0.00028	CcSEcCtD
Haloperidol—Urticaria—Paclitaxel—breast cancer	2.64e-05	0.00028	CcSEcCtD
Haloperidol—Hyperhidrosis—Capecitabine—breast cancer	2.64e-05	0.000279	CcSEcCtD
Haloperidol—Hypotension—Docetaxel—breast cancer	2.63e-05	0.000279	CcSEcCtD
Haloperidol—Connective tissue disorder—Epirubicin—breast cancer	2.63e-05	0.000278	CcSEcCtD
Haloperidol—Body temperature increased—Paclitaxel—breast cancer	2.63e-05	0.000278	CcSEcCtD
Haloperidol—Urethral disorder—Epirubicin—breast cancer	2.62e-05	0.000278	CcSEcCtD
Haloperidol—Hepatobiliary disease—Doxorubicin—breast cancer	2.61e-05	0.000276	CcSEcCtD
Haloperidol—Anorexia—Capecitabine—breast cancer	2.6e-05	0.000275	CcSEcCtD
Haloperidol—Angiopathy—Methotrexate—breast cancer	2.59e-05	0.000275	CcSEcCtD
Haloperidol—Vomiting—Mitoxantrone—breast cancer	2.59e-05	0.000275	CcSEcCtD
Haloperidol—Vomiting—Irinotecan—breast cancer	2.59e-05	0.000275	CcSEcCtD
Haloperidol—Immune system disorder—Methotrexate—breast cancer	2.58e-05	0.000274	CcSEcCtD
Haloperidol—Dizziness—Fluorouracil—breast cancer	2.58e-05	0.000273	CcSEcCtD
Haloperidol—Visual impairment—Epirubicin—breast cancer	2.58e-05	0.000273	CcSEcCtD
Haloperidol—Mediastinal disorder—Methotrexate—breast cancer	2.58e-05	0.000273	CcSEcCtD
Haloperidol—Agranulocytosis—Doxorubicin—breast cancer	2.57e-05	0.000273	CcSEcCtD
Haloperidol—Rash—Irinotecan—breast cancer	2.57e-05	0.000272	CcSEcCtD
Haloperidol—Rash—Mitoxantrone—breast cancer	2.57e-05	0.000272	CcSEcCtD
Haloperidol—Dermatitis—Irinotecan—breast cancer	2.57e-05	0.000272	CcSEcCtD
Haloperidol—Dermatitis—Mitoxantrone—breast cancer	2.57e-05	0.000272	CcSEcCtD
Haloperidol—Headache—Irinotecan—breast cancer	2.55e-05	0.000271	CcSEcCtD
Haloperidol—Headache—Mitoxantrone—breast cancer	2.55e-05	0.000271	CcSEcCtD
Haloperidol—Hypotension—Capecitabine—breast cancer	2.55e-05	0.00027	CcSEcCtD
Haloperidol—Insomnia—Docetaxel—breast cancer	2.55e-05	0.00027	CcSEcCtD
Haloperidol—Alopecia—Methotrexate—breast cancer	2.53e-05	0.000268	CcSEcCtD
Haloperidol—Vomiting—Gemcitabine—breast cancer	2.52e-05	0.000267	CcSEcCtD
Haloperidol—Dyspnoea—Docetaxel—breast cancer	2.51e-05	0.000266	CcSEcCtD
Haloperidol—Somnolence—Docetaxel—breast cancer	2.51e-05	0.000265	CcSEcCtD
Haloperidol—Mental disorder—Methotrexate—breast cancer	2.5e-05	0.000265	CcSEcCtD
Haloperidol—Rash—Gemcitabine—breast cancer	2.5e-05	0.000265	CcSEcCtD
Haloperidol—Dermatitis—Gemcitabine—breast cancer	2.5e-05	0.000265	CcSEcCtD
Haloperidol—Eye disorder—Epirubicin—breast cancer	2.5e-05	0.000265	CcSEcCtD
Haloperidol—Malnutrition—Methotrexate—breast cancer	2.49e-05	0.000264	CcSEcCtD
Haloperidol—Headache—Gemcitabine—breast cancer	2.49e-05	0.000264	CcSEcCtD
Haloperidol—Cardiac disorder—Epirubicin—breast cancer	2.48e-05	0.000263	CcSEcCtD
Haloperidol—Vomiting—Fluorouracil—breast cancer	2.48e-05	0.000263	CcSEcCtD
Haloperidol—Dyspepsia—Docetaxel—breast cancer	2.48e-05	0.000263	CcSEcCtD
Haloperidol—Hepatitis—Doxorubicin—breast cancer	2.48e-05	0.000262	CcSEcCtD
Haloperidol—Insomnia—Capecitabine—breast cancer	2.47e-05	0.000261	CcSEcCtD
Haloperidol—Rash—Fluorouracil—breast cancer	2.46e-05	0.000261	CcSEcCtD
Haloperidol—Dermatitis—Fluorouracil—breast cancer	2.46e-05	0.000261	CcSEcCtD
Haloperidol—Decreased appetite—Docetaxel—breast cancer	2.45e-05	0.000259	CcSEcCtD
Haloperidol—Hypersensitivity—Paclitaxel—breast cancer	2.45e-05	0.000259	CcSEcCtD
Haloperidol—Headache—Fluorouracil—breast cancer	2.45e-05	0.000259	CcSEcCtD
Haloperidol—Urinary tract disorder—Doxorubicin—breast cancer	2.44e-05	0.000259	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Docetaxel—breast cancer	2.43e-05	0.000258	CcSEcCtD
Haloperidol—Connective tissue disorder—Doxorubicin—breast cancer	2.43e-05	0.000258	CcSEcCtD
Haloperidol—Dyspnoea—Capecitabine—breast cancer	2.43e-05	0.000258	CcSEcCtD
Haloperidol—Angiopathy—Epirubicin—breast cancer	2.43e-05	0.000257	CcSEcCtD
Haloperidol—Urethral disorder—Doxorubicin—breast cancer	2.43e-05	0.000257	CcSEcCtD
Haloperidol—Nausea—Irinotecan—breast cancer	2.42e-05	0.000257	CcSEcCtD
Haloperidol—Nausea—Mitoxantrone—breast cancer	2.42e-05	0.000257	CcSEcCtD
Haloperidol—Immune system disorder—Epirubicin—breast cancer	2.42e-05	0.000256	CcSEcCtD
Haloperidol—Mediastinal disorder—Epirubicin—breast cancer	2.41e-05	0.000255	CcSEcCtD
Haloperidol—Constipation—Docetaxel—breast cancer	2.41e-05	0.000255	CcSEcCtD
Haloperidol—Dyspepsia—Capecitabine—breast cancer	2.4e-05	0.000254	CcSEcCtD
Haloperidol—Visual impairment—Doxorubicin—breast cancer	2.39e-05	0.000253	CcSEcCtD
Haloperidol—Decreased appetite—Capecitabine—breast cancer	2.37e-05	0.000251	CcSEcCtD
Haloperidol—Alopecia—Epirubicin—breast cancer	2.36e-05	0.00025	CcSEcCtD
Haloperidol—Nausea—Gemcitabine—breast cancer	2.36e-05	0.00025	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Capecitabine—breast cancer	2.36e-05	0.00025	CcSEcCtD
Haloperidol—Pruritus—Paclitaxel—breast cancer	2.35e-05	0.000249	CcSEcCtD
Haloperidol—Vision blurred—Methotrexate—breast cancer	2.35e-05	0.000248	CcSEcCtD
Haloperidol—Mental disorder—Epirubicin—breast cancer	2.34e-05	0.000248	CcSEcCtD
Haloperidol—Constipation—Capecitabine—breast cancer	2.33e-05	0.000247	CcSEcCtD
Haloperidol—Malnutrition—Epirubicin—breast cancer	2.33e-05	0.000247	CcSEcCtD
Haloperidol—Feeling abnormal—Docetaxel—breast cancer	2.32e-05	0.000246	CcSEcCtD
Haloperidol—Nausea—Fluorouracil—breast cancer	2.32e-05	0.000246	CcSEcCtD
Haloperidol—Eye disorder—Doxorubicin—breast cancer	2.31e-05	0.000245	CcSEcCtD
Haloperidol—Anaemia—Methotrexate—breast cancer	2.3e-05	0.000244	CcSEcCtD
Haloperidol—Cardiac disorder—Doxorubicin—breast cancer	2.3e-05	0.000243	CcSEcCtD
Haloperidol—Diarrhoea—Paclitaxel—breast cancer	2.27e-05	0.000241	CcSEcCtD
Haloperidol—Feeling abnormal—Capecitabine—breast cancer	2.25e-05	0.000238	CcSEcCtD
Haloperidol—Angiopathy—Doxorubicin—breast cancer	2.25e-05	0.000238	CcSEcCtD
Haloperidol—Muscle spasms—Epirubicin—breast cancer	2.24e-05	0.000237	CcSEcCtD
Haloperidol—Immune system disorder—Doxorubicin—breast cancer	2.24e-05	0.000237	CcSEcCtD
Haloperidol—Vertigo—Methotrexate—breast cancer	2.24e-05	0.000237	CcSEcCtD
Haloperidol—Mediastinal disorder—Doxorubicin—breast cancer	2.23e-05	0.000236	CcSEcCtD
Haloperidol—Body temperature increased—Docetaxel—breast cancer	2.23e-05	0.000236	CcSEcCtD
Haloperidol—Leukopenia—Methotrexate—breast cancer	2.23e-05	0.000236	CcSEcCtD
Haloperidol—Dizziness—Paclitaxel—breast cancer	2.2e-05	0.000233	CcSEcCtD
Haloperidol—Vision blurred—Epirubicin—breast cancer	2.19e-05	0.000233	CcSEcCtD
Haloperidol—Alopecia—Doxorubicin—breast cancer	2.19e-05	0.000232	CcSEcCtD
Haloperidol—Mental disorder—Doxorubicin—breast cancer	2.17e-05	0.00023	CcSEcCtD
Haloperidol—Urticaria—Capecitabine—breast cancer	2.17e-05	0.00023	CcSEcCtD
Haloperidol—Body temperature increased—Capecitabine—breast cancer	2.16e-05	0.000228	CcSEcCtD
Haloperidol—Convulsion—Methotrexate—breast cancer	2.16e-05	0.000228	CcSEcCtD
Haloperidol—Malnutrition—Doxorubicin—breast cancer	2.16e-05	0.000228	CcSEcCtD
Haloperidol—Anaemia—Epirubicin—breast cancer	2.15e-05	0.000228	CcSEcCtD
Haloperidol—Agitation—Epirubicin—breast cancer	2.14e-05	0.000227	CcSEcCtD
Haloperidol—Vomiting—Paclitaxel—breast cancer	2.11e-05	0.000224	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	2.1e-05	0.000223	CcSEcCtD
Haloperidol—Rash—Paclitaxel—breast cancer	2.1e-05	0.000222	CcSEcCtD
Haloperidol—Dermatitis—Paclitaxel—breast cancer	2.09e-05	0.000222	CcSEcCtD
Haloperidol—Vertigo—Epirubicin—breast cancer	2.09e-05	0.000222	CcSEcCtD
Haloperidol—Leukopenia—Epirubicin—breast cancer	2.08e-05	0.000221	CcSEcCtD
Haloperidol—Headache—Paclitaxel—breast cancer	2.08e-05	0.000221	CcSEcCtD
Haloperidol—Hypersensitivity—Docetaxel—breast cancer	2.08e-05	0.00022	CcSEcCtD
Haloperidol—Muscle spasms—Doxorubicin—breast cancer	2.07e-05	0.000219	CcSEcCtD
Haloperidol—Confusional state—Methotrexate—breast cancer	2.05e-05	0.000217	CcSEcCtD
Haloperidol—Anaphylactic shock—Methotrexate—breast cancer	2.03e-05	0.000215	CcSEcCtD
Haloperidol—Vision blurred—Doxorubicin—breast cancer	2.03e-05	0.000215	CcSEcCtD
Haloperidol—Convulsion—Epirubicin—breast cancer	2.02e-05	0.000214	CcSEcCtD
Haloperidol—Hypertension—Epirubicin—breast cancer	2.01e-05	0.000213	CcSEcCtD
Haloperidol—Hypersensitivity—Capecitabine—breast cancer	2.01e-05	0.000213	CcSEcCtD
Haloperidol—Pruritus—Docetaxel—breast cancer	1.99e-05	0.000211	CcSEcCtD
Haloperidol—Nervous system disorder—Methotrexate—breast cancer	1.99e-05	0.000211	CcSEcCtD
Haloperidol—Anaemia—Doxorubicin—breast cancer	1.99e-05	0.000211	CcSEcCtD
Haloperidol—Thrombocytopenia—Methotrexate—breast cancer	1.99e-05	0.000211	CcSEcCtD
Haloperidol—Agitation—Doxorubicin—breast cancer	1.98e-05	0.00021	CcSEcCtD
Haloperidol—Anxiety—Epirubicin—breast cancer	1.98e-05	0.000209	CcSEcCtD
Haloperidol—Nausea—Paclitaxel—breast cancer	1.97e-05	0.000209	CcSEcCtD
Haloperidol—Skin disorder—Methotrexate—breast cancer	1.97e-05	0.000209	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	1.97e-05	0.000209	CcSEcCtD
Haloperidol—Hyperhidrosis—Methotrexate—breast cancer	1.96e-05	0.000208	CcSEcCtD
Haloperidol—Dry mouth—Epirubicin—breast cancer	1.94e-05	0.000205	CcSEcCtD
Haloperidol—Vertigo—Doxorubicin—breast cancer	1.94e-05	0.000205	CcSEcCtD
Haloperidol—Anorexia—Methotrexate—breast cancer	1.94e-05	0.000205	CcSEcCtD
Haloperidol—Pruritus—Capecitabine—breast cancer	1.93e-05	0.000204	CcSEcCtD
Haloperidol—Leukopenia—Doxorubicin—breast cancer	1.93e-05	0.000204	CcSEcCtD
Haloperidol—Diarrhoea—Docetaxel—breast cancer	1.93e-05	0.000204	CcSEcCtD
Haloperidol—Confusional state—Epirubicin—breast cancer	1.92e-05	0.000203	CcSEcCtD
Haloperidol—Anaphylactic shock—Epirubicin—breast cancer	1.9e-05	0.000201	CcSEcCtD
Haloperidol—Oedema—Epirubicin—breast cancer	1.9e-05	0.000201	CcSEcCtD
Haloperidol—Hypotension—Methotrexate—breast cancer	1.9e-05	0.000201	CcSEcCtD
Haloperidol—Convulsion—Doxorubicin—breast cancer	1.87e-05	0.000198	CcSEcCtD
Haloperidol—Diarrhoea—Capecitabine—breast cancer	1.87e-05	0.000198	CcSEcCtD
Haloperidol—Nervous system disorder—Epirubicin—breast cancer	1.86e-05	0.000197	CcSEcCtD
Haloperidol—Dizziness—Docetaxel—breast cancer	1.86e-05	0.000197	CcSEcCtD
Haloperidol—Thrombocytopenia—Epirubicin—breast cancer	1.86e-05	0.000197	CcSEcCtD
Haloperidol—Hypertension—Doxorubicin—breast cancer	1.86e-05	0.000197	CcSEcCtD
Haloperidol—Tachycardia—Epirubicin—breast cancer	1.86e-05	0.000197	CcSEcCtD
Haloperidol—Skin disorder—Epirubicin—breast cancer	1.85e-05	0.000196	CcSEcCtD
Haloperidol—Hyperhidrosis—Epirubicin—breast cancer	1.84e-05	0.000195	CcSEcCtD
Haloperidol—Insomnia—Methotrexate—breast cancer	1.84e-05	0.000195	CcSEcCtD
Haloperidol—Anxiety—Doxorubicin—breast cancer	1.83e-05	0.000194	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	1.82e-05	0.000193	CcSEcCtD
Haloperidol—Anorexia—Epirubicin—breast cancer	1.81e-05	0.000192	CcSEcCtD
Haloperidol—Dyspnoea—Methotrexate—breast cancer	1.81e-05	0.000192	CcSEcCtD
Haloperidol—Somnolence—Methotrexate—breast cancer	1.81e-05	0.000191	CcSEcCtD
Haloperidol—Dizziness—Capecitabine—breast cancer	1.8e-05	0.000191	CcSEcCtD
Haloperidol—Dry mouth—Doxorubicin—breast cancer	1.79e-05	0.00019	CcSEcCtD
Haloperidol—Vomiting—Docetaxel—breast cancer	1.79e-05	0.00019	CcSEcCtD
Haloperidol—Dyspepsia—Methotrexate—breast cancer	1.79e-05	0.000189	CcSEcCtD
Haloperidol—Rash—Docetaxel—breast cancer	1.78e-05	0.000188	CcSEcCtD
Haloperidol—Hypotension—Epirubicin—breast cancer	1.78e-05	0.000188	CcSEcCtD
Haloperidol—Dermatitis—Docetaxel—breast cancer	1.78e-05	0.000188	CcSEcCtD
Haloperidol—Confusional state—Doxorubicin—breast cancer	1.77e-05	0.000188	CcSEcCtD
Haloperidol—Decreased appetite—Methotrexate—breast cancer	1.77e-05	0.000187	CcSEcCtD
Haloperidol—Headache—Docetaxel—breast cancer	1.77e-05	0.000187	CcSEcCtD
Haloperidol—Anaphylactic shock—Doxorubicin—breast cancer	1.76e-05	0.000186	CcSEcCtD
Haloperidol—Oedema—Doxorubicin—breast cancer	1.76e-05	0.000186	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Methotrexate—breast cancer	1.75e-05	0.000186	CcSEcCtD
Haloperidol—Vomiting—Capecitabine—breast cancer	1.73e-05	0.000184	CcSEcCtD
Haloperidol—Nervous system disorder—Doxorubicin—breast cancer	1.72e-05	0.000183	CcSEcCtD
Haloperidol—Thrombocytopenia—Doxorubicin—breast cancer	1.72e-05	0.000182	CcSEcCtD
Haloperidol—Rash—Capecitabine—breast cancer	1.72e-05	0.000182	CcSEcCtD
Haloperidol—Insomnia—Epirubicin—breast cancer	1.72e-05	0.000182	CcSEcCtD
Haloperidol—Dermatitis—Capecitabine—breast cancer	1.72e-05	0.000182	CcSEcCtD
Haloperidol—Tachycardia—Doxorubicin—breast cancer	1.72e-05	0.000182	CcSEcCtD
Haloperidol—Headache—Capecitabine—breast cancer	1.71e-05	0.000181	CcSEcCtD
Haloperidol—Skin disorder—Doxorubicin—breast cancer	1.71e-05	0.000181	CcSEcCtD
Haloperidol—Hyperhidrosis—Doxorubicin—breast cancer	1.7e-05	0.00018	CcSEcCtD
Haloperidol—Dyspnoea—Epirubicin—breast cancer	1.69e-05	0.00018	CcSEcCtD
Haloperidol—Somnolence—Epirubicin—breast cancer	1.69e-05	0.000179	CcSEcCtD
Haloperidol—Anorexia—Doxorubicin—breast cancer	1.68e-05	0.000178	CcSEcCtD
Haloperidol—Nausea—Docetaxel—breast cancer	1.67e-05	0.000177	CcSEcCtD
Haloperidol—Feeling abnormal—Methotrexate—breast cancer	1.67e-05	0.000177	CcSEcCtD
Haloperidol—Dyspepsia—Epirubicin—breast cancer	1.67e-05	0.000177	CcSEcCtD
Haloperidol—Decreased appetite—Epirubicin—breast cancer	1.65e-05	0.000175	CcSEcCtD
Haloperidol—Hypotension—Doxorubicin—breast cancer	1.64e-05	0.000174	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Epirubicin—breast cancer	1.64e-05	0.000174	CcSEcCtD
Haloperidol—Constipation—Epirubicin—breast cancer	1.63e-05	0.000172	CcSEcCtD
Haloperidol—Nausea—Capecitabine—breast cancer	1.62e-05	0.000172	CcSEcCtD
Haloperidol—Urticaria—Methotrexate—breast cancer	1.61e-05	0.000171	CcSEcCtD
Haloperidol—Body temperature increased—Methotrexate—breast cancer	1.61e-05	0.00017	CcSEcCtD
Haloperidol—Insomnia—Doxorubicin—breast cancer	1.59e-05	0.000169	CcSEcCtD
Haloperidol—Dyspnoea—Doxorubicin—breast cancer	1.57e-05	0.000166	CcSEcCtD
Haloperidol—Feeling abnormal—Epirubicin—breast cancer	1.57e-05	0.000166	CcSEcCtD
Haloperidol—Somnolence—Doxorubicin—breast cancer	1.56e-05	0.000166	CcSEcCtD
Haloperidol—Dyspepsia—Doxorubicin—breast cancer	1.55e-05	0.000164	CcSEcCtD
Haloperidol—Decreased appetite—Doxorubicin—breast cancer	1.53e-05	0.000162	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Doxorubicin—breast cancer	1.52e-05	0.000161	CcSEcCtD
Haloperidol—Urticaria—Epirubicin—breast cancer	1.51e-05	0.00016	CcSEcCtD
Haloperidol—Constipation—Doxorubicin—breast cancer	1.5e-05	0.000159	CcSEcCtD
Haloperidol—Body temperature increased—Epirubicin—breast cancer	1.5e-05	0.000159	CcSEcCtD
Haloperidol—Hypersensitivity—Methotrexate—breast cancer	1.5e-05	0.000159	CcSEcCtD
Haloperidol—Feeling abnormal—Doxorubicin—breast cancer	1.45e-05	0.000154	CcSEcCtD
Haloperidol—Pruritus—Methotrexate—breast cancer	1.44e-05	0.000152	CcSEcCtD
Haloperidol—Hypersensitivity—Epirubicin—breast cancer	1.4e-05	0.000148	CcSEcCtD
Haloperidol—Urticaria—Doxorubicin—breast cancer	1.4e-05	0.000148	CcSEcCtD
Haloperidol—Body temperature increased—Doxorubicin—breast cancer	1.39e-05	0.000147	CcSEcCtD
Haloperidol—Diarrhoea—Methotrexate—breast cancer	1.39e-05	0.000147	CcSEcCtD
Haloperidol—Pruritus—Epirubicin—breast cancer	1.34e-05	0.000142	CcSEcCtD
Haloperidol—Dizziness—Methotrexate—breast cancer	1.34e-05	0.000142	CcSEcCtD
Haloperidol—Diarrhoea—Epirubicin—breast cancer	1.3e-05	0.000138	CcSEcCtD
Haloperidol—Hypersensitivity—Doxorubicin—breast cancer	1.3e-05	0.000137	CcSEcCtD
Haloperidol—Vomiting—Methotrexate—breast cancer	1.29e-05	0.000137	CcSEcCtD
Haloperidol—Rash—Methotrexate—breast cancer	1.28e-05	0.000136	CcSEcCtD
Haloperidol—Dermatitis—Methotrexate—breast cancer	1.28e-05	0.000136	CcSEcCtD
Haloperidol—Headache—Methotrexate—breast cancer	1.27e-05	0.000135	CcSEcCtD
Haloperidol—Dizziness—Epirubicin—breast cancer	1.26e-05	0.000133	CcSEcCtD
Haloperidol—Pruritus—Doxorubicin—breast cancer	1.24e-05	0.000132	CcSEcCtD
Haloperidol—Vomiting—Epirubicin—breast cancer	1.21e-05	0.000128	CcSEcCtD
Haloperidol—Nausea—Methotrexate—breast cancer	1.21e-05	0.000128	CcSEcCtD
Haloperidol—Diarrhoea—Doxorubicin—breast cancer	1.2e-05	0.000127	CcSEcCtD
Haloperidol—Rash—Epirubicin—breast cancer	1.2e-05	0.000127	CcSEcCtD
Haloperidol—Dermatitis—Epirubicin—breast cancer	1.2e-05	0.000127	CcSEcCtD
Haloperidol—Headache—Epirubicin—breast cancer	1.19e-05	0.000126	CcSEcCtD
Haloperidol—Dizziness—Doxorubicin—breast cancer	1.16e-05	0.000123	CcSEcCtD
Haloperidol—Nausea—Epirubicin—breast cancer	1.13e-05	0.00012	CcSEcCtD
Haloperidol—Vomiting—Doxorubicin—breast cancer	1.12e-05	0.000118	CcSEcCtD
Haloperidol—Rash—Doxorubicin—breast cancer	1.11e-05	0.000117	CcSEcCtD
Haloperidol—Dermatitis—Doxorubicin—breast cancer	1.11e-05	0.000117	CcSEcCtD
Haloperidol—Headache—Doxorubicin—breast cancer	1.1e-05	0.000117	CcSEcCtD
Haloperidol—Nausea—Doxorubicin—breast cancer	1.04e-05	0.000111	CcSEcCtD
Haloperidol—DRD2—Signaling Pathways—RAF1—breast cancer	7.61e-07	1.07e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—STAT3—breast cancer	7.61e-07	1.07e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—VEGFA—breast cancer	7.58e-07	1.07e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—RELA—breast cancer	7.58e-07	1.07e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—PIK3CA—breast cancer	7.55e-07	1.06e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—ERBB2—breast cancer	7.53e-07	1.06e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—PIK3CA—breast cancer	7.53e-07	1.06e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—KRAS—breast cancer	7.53e-07	1.06e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—MDM2—breast cancer	7.52e-07	1.06e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—STAT3—breast cancer	7.51e-07	1.06e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—MDM2—breast cancer	7.5e-07	1.06e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—MYC—breast cancer	7.5e-07	1.06e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—RAF1—breast cancer	7.49e-07	1.06e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—TGFB1—breast cancer	7.48e-07	1.05e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—RAF1—breast cancer	7.48e-07	1.05e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—NOS3—breast cancer	7.46e-07	1.05e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—RELA—breast cancer	7.46e-07	1.05e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CYP1B1—breast cancer	7.45e-07	1.05e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—RELA—breast cancer	7.44e-07	1.05e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—PIK3CB—breast cancer	7.43e-07	1.05e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—MTOR—breast cancer	7.43e-07	1.05e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—CAV1—breast cancer	7.43e-07	1.05e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—ERBB2—breast cancer	7.41e-07	1.04e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—ERBB2—breast cancer	7.4e-07	1.04e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—GPX1—breast cancer	7.39e-07	1.04e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—KRAS—breast cancer	7.37e-07	1.04e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—CAV1—breast cancer	7.37e-07	1.04e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PIK3CG—breast cancer	7.36e-07	1.04e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—EGFR—breast cancer	7.33e-07	1.03e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—CYP1A1—breast cancer	7.32e-07	1.03e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—PIK3CB—breast cancer	7.31e-07	1.03e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—MTOR—breast cancer	7.31e-07	1.03e-05	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—PIK3CA—breast cancer	7.31e-07	1.03e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—HSP90AA1—breast cancer	7.31e-07	1.03e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—MTOR—breast cancer	7.3e-07	1.03e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—PIK3CB—breast cancer	7.3e-07	1.03e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PIK3CB—breast cancer	7.29e-07	1.03e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—MAPK3—breast cancer	7.27e-07	1.02e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—ERCC2—breast cancer	7.26e-07	1.02e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—KRAS—breast cancer	7.26e-07	1.02e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PTGS2—breast cancer	7.23e-07	1.02e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PIK3CG—breast cancer	7.18e-07	1.01e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—MAPK3—breast cancer	7.17e-07	1.01e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CXCL8—breast cancer	7.14e-07	1.01e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—NCOA1—breast cancer	7.11e-07	1e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—HRAS—breast cancer	7.1e-07	1e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—MYC—breast cancer	7.07e-07	9.96e-06	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—TGFB1—breast cancer	7.05e-07	9.94e-06	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	7.04e-07	9.91e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CXCL8—breast cancer	7.03e-07	9.9e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CXCL8—breast cancer	7.01e-07	9.88e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—STK11—breast cancer	7.01e-07	9.87e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CYP19A1—breast cancer	7.01e-07	9.87e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—HRAS—breast cancer	6.98e-07	9.84e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CDKN1B—breast cancer	6.98e-07	9.83e-06	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—MYC—breast cancer	6.98e-07	9.83e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—HRAS—breast cancer	6.97e-07	9.82e-06	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—TGFB1—breast cancer	6.96e-07	9.8e-06	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—KRAS—breast cancer	6.93e-07	9.76e-06	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—PIK3CA—breast cancer	6.92e-07	9.75e-06	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—EGFR—breast cancer	6.92e-07	9.74e-06	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—AKT1—breast cancer	6.9e-07	9.72e-06	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PIK3CB—breast cancer	6.89e-07	9.71e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CDKN1B—breast cancer	6.86e-07	9.67e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CDKN1B—breast cancer	6.85e-07	9.65e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CASP3—breast cancer	6.84e-07	9.63e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—IL2—breast cancer	6.83e-07	9.62e-06	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PTGS2—breast cancer	6.83e-07	9.62e-06	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—MTHFR—breast cancer	6.82e-07	9.61e-06	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—EGFR—breast cancer	6.82e-07	9.61e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—IL6—breast cancer	6.79e-07	9.57e-06	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—AKT1—breast cancer	6.79e-07	9.57e-06	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—AKT1—breast cancer	6.78e-07	9.55e-06	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—PIK3CA—breast cancer	6.77e-07	9.55e-06	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PIK3CG—breast cancer	6.77e-07	9.53e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CASP3—breast cancer	6.73e-07	9.48e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—IL2—breast cancer	6.72e-07	9.46e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CASP3—breast cancer	6.71e-07	9.46e-06	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PIK3CG—breast cancer	6.71e-07	9.45e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—IL2—breast cancer	6.7e-07	9.44e-06	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—TP53—breast cancer	6.69e-07	9.43e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—IL6—breast cancer	6.68e-07	9.42e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—IL6—breast cancer	6.67e-07	9.4e-06	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—PIK3CA—breast cancer	6.67e-07	9.39e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CCND1—breast cancer	6.65e-07	9.38e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—JUN—breast cancer	6.64e-07	9.36e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CTNNB1—breast cancer	6.59e-07	9.29e-06	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—TP53—breast cancer	6.55e-07	9.23e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CCND1—breast cancer	6.55e-07	9.23e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—JUN—breast cancer	6.53e-07	9.21e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CCND1—breast cancer	6.53e-07	9.21e-06	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—KRAS—breast cancer	6.53e-07	9.2e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—JUN—breast cancer	6.52e-07	9.19e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—COMT—breast cancer	6.51e-07	9.18e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CTNNB1—breast cancer	6.48e-07	9.14e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—GSTP1—breast cancer	6.48e-07	9.14e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CTNNB1—breast cancer	6.47e-07	9.12e-06	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PIK3CD—breast cancer	6.47e-07	9.11e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—MMP9—breast cancer	6.46e-07	9.1e-06	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—TP53—breast cancer	6.45e-07	9.09e-06	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—KRAS—breast cancer	6.45e-07	9.08e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CDKN1A—breast cancer	6.44e-07	9.07e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—PTEN—breast cancer	6.42e-07	9.05e-06	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—HRAS—breast cancer	6.4e-07	9.02e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—HMOX1—breast cancer	6.39e-07	9.01e-06	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—ALB—breast cancer	6.39e-07	9e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—ITPR1—breast cancer	6.38e-07	8.99e-06	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—PIK3CA—breast cancer	6.36e-07	8.97e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—MMP9—breast cancer	6.36e-07	8.96e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—MMP9—breast cancer	6.34e-07	8.94e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CDKN1A—breast cancer	6.33e-07	8.92e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CDKN1A—breast cancer	6.32e-07	8.91e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—PTEN—breast cancer	6.32e-07	8.9e-06	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PIK3CD—breast cancer	6.31e-07	8.9e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—PTEN—breast cancer	6.31e-07	8.89e-06	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PTEN—breast cancer	6.3e-07	8.88e-06	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—CAV1—breast cancer	6.29e-07	8.87e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—MAPK8—breast cancer	6.28e-07	8.85e-06	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—HRAS—breast cancer	6.27e-07	8.83e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—AKT1—breast cancer	6.27e-07	8.83e-06	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—ALB—breast cancer	6.23e-07	8.78e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—MAPK8—breast cancer	6.18e-07	8.71e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—MAPK8—breast cancer	6.17e-07	8.69e-06	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—HRAS—breast cancer	6.17e-07	8.69e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—AKT1—breast cancer	6.17e-07	8.69e-06	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—TP53—breast cancer	6.16e-07	8.67e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—AKT1—breast cancer	6.15e-07	8.67e-06	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—PIK3CA—breast cancer	6.15e-07	8.66e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—ABCB1—breast cancer	6.14e-07	8.65e-06	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—IL6—breast cancer	6.13e-07	8.63e-06	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—NOS3—breast cancer	6.11e-07	8.61e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—TYMS—breast cancer	6.03e-07	8.49e-06	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	6.01e-07	8.47e-06	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—PIK3CA—breast cancer	6e-07	8.46e-06	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—IL6—breast cancer	6e-07	8.45e-06	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—AKT1—breast cancer	5.97e-07	8.42e-06	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—NOS3—breast cancer	5.96e-07	8.4e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—NCOR1—breast cancer	5.96e-07	8.4e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PLA2G4A—breast cancer	5.96e-07	8.4e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—GSTM1—breast cancer	5.96e-07	8.4e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—SRC—breast cancer	5.96e-07	8.39e-06	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PTEN—breast cancer	5.95e-07	8.39e-06	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PIK3CD—breast cancer	5.95e-07	8.38e-06	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—PIK3CA—breast cancer	5.92e-07	8.34e-06	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—IL6—breast cancer	5.9e-07	8.32e-06	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PIK3CD—breast cancer	5.9e-07	8.31e-06	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—HRAS—breast cancer	5.89e-07	8.3e-06	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—ALB—breast cancer	5.87e-07	8.27e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—SRC—breast cancer	5.86e-07	8.26e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—SRC—breast cancer	5.85e-07	8.24e-06	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—ALB—breast cancer	5.82e-07	8.2e-06	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—TP53—breast cancer	5.81e-07	8.18e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—VEGFA—breast cancer	5.8e-07	8.17e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—STAT3—breast cancer	5.74e-07	8.09e-06	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PIK3CG—breast cancer	5.73e-07	8.08e-06	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—TP53—breast cancer	5.73e-07	8.07e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—VEGFA—breast cancer	5.71e-07	8.04e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—GPX1—breast cancer	5.71e-07	8.04e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—VEGFA—breast cancer	5.7e-07	8.03e-06	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—AKT1—breast cancer	5.65e-07	7.96e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—STAT3—breast cancer	5.65e-07	7.96e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CYP1A1—breast cancer	5.65e-07	7.96e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—STAT3—breast cancer	5.64e-07	7.95e-06	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PIK3CB—breast cancer	5.64e-07	7.94e-06	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—IL6—breast cancer	5.64e-07	7.94e-06	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—NOS3—breast cancer	5.62e-07	7.92e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—ERCC2—breast cancer	5.6e-07	7.89e-06	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PTGS2—breast cancer	5.59e-07	7.87e-06	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—NOS3—breast cancer	5.57e-07	7.85e-06	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—HRAS—breast cancer	5.55e-07	7.82e-06	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—AKT1—breast cancer	5.53e-07	7.8e-06	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PIK3CB—breast cancer	5.5e-07	7.75e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—MAPK3—breast cancer	5.49e-07	7.73e-06	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—HRAS—breast cancer	5.48e-07	7.72e-06	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PTGS2—breast cancer	5.45e-07	7.68e-06	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—AKT1—breast cancer	5.45e-07	7.67e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—MAPK3—breast cancer	5.4e-07	7.61e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—MAPK3—breast cancer	5.39e-07	7.59e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—MYC—breast cancer	5.34e-07	7.52e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—TGFB1—breast cancer	5.32e-07	7.5e-06	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—IL6—breast cancer	5.31e-07	7.49e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—MTHFR—breast cancer	5.27e-07	7.42e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—MYC—breast cancer	5.25e-07	7.4e-06	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—IL6—breast cancer	5.24e-07	7.39e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—MYC—breast cancer	5.24e-07	7.38e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—TGFB1—breast cancer	5.24e-07	7.38e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—TGFB1—breast cancer	5.23e-07	7.37e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—EGFR—breast cancer	5.22e-07	7.36e-06	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—AKT1—breast cancer	5.2e-07	7.33e-06	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PIK3CB—breast cancer	5.19e-07	7.31e-06	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PIK3CB—breast cancer	5.14e-07	7.24e-06	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PTGS2—breast cancer	5.14e-07	7.24e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—EGFR—breast cancer	5.14e-07	7.24e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—EGFR—breast cancer	5.13e-07	7.22e-06	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PTGS2—breast cancer	5.09e-07	7.18e-06	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PIK3CD—breast cancer	5.04e-07	7.1e-06	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—AKT1—breast cancer	5.02e-07	7.08e-06	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—ALB—breast cancer	4.98e-07	7.01e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—KRAS—breast cancer	4.93e-07	6.95e-06	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—AKT1—breast cancer	4.9e-07	6.91e-06	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PTEN—breast cancer	4.87e-07	6.86e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CAV1—breast cancer	4.86e-07	6.84e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—KRAS—breast cancer	4.85e-07	6.84e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—KRAS—breast cancer	4.84e-07	6.82e-06	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—AKT1—breast cancer	4.84e-07	6.82e-06	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—NOS3—breast cancer	4.76e-07	6.71e-06	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PTEN—breast cancer	4.75e-07	6.7e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—PIK3CA—breast cancer	4.53e-07	6.38e-06	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PTEN—breast cancer	4.48e-07	6.31e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—PIK3CA—breast cancer	4.46e-07	6.28e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—PIK3CA—breast cancer	4.45e-07	6.27e-06	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PIK3CA—breast cancer	4.45e-07	6.26e-06	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PTEN—breast cancer	4.44e-07	6.26e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PIK3CG—breast cancer	4.42e-07	6.23e-06	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PIK3CB—breast cancer	4.39e-07	6.19e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—TP53—breast cancer	4.38e-07	6.18e-06	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PTGS2—breast cancer	4.35e-07	6.13e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—TP53—breast cancer	4.31e-07	6.08e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—TP53—breast cancer	4.3e-07	6.06e-06	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PIK3CA—breast cancer	4.2e-07	5.92e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—HRAS—breast cancer	4.19e-07	5.91e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—HRAS—breast cancer	4.13e-07	5.81e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—HRAS—breast cancer	4.12e-07	5.8e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—IL6—breast cancer	4.01e-07	5.65e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—IL6—breast cancer	3.95e-07	5.56e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—IL6—breast cancer	3.94e-07	5.55e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PIK3CD—breast cancer	3.89e-07	5.48e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—ALB—breast cancer	3.84e-07	5.41e-06	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PTEN—breast cancer	3.8e-07	5.35e-06	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—AKT1—breast cancer	3.7e-07	5.22e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—NOS3—breast cancer	3.67e-07	5.17e-06	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—AKT1—breast cancer	3.64e-07	5.13e-06	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—AKT1—breast cancer	3.63e-07	5.12e-06	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—AKT1—breast cancer	3.63e-07	5.12e-06	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PIK3CA—breast cancer	3.44e-07	4.84e-06	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—AKT1—breast cancer	3.43e-07	4.83e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PIK3CB—breast cancer	3.39e-07	4.78e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PTGS2—breast cancer	3.36e-07	4.73e-06	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PIK3CA—breast cancer	3.35e-07	4.73e-06	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PIK3CA—breast cancer	3.16e-07	4.45e-06	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PIK3CA—breast cancer	3.13e-07	4.42e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PTEN—breast cancer	2.93e-07	4.13e-06	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—AKT1—breast cancer	2.81e-07	3.96e-06	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—AKT1—breast cancer	2.74e-07	3.86e-06	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PIK3CA—breast cancer	2.68e-07	3.77e-06	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—AKT1—breast cancer	2.58e-07	3.64e-06	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—AKT1—breast cancer	2.56e-07	3.61e-06	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—AKT1—breast cancer	2.19e-07	3.08e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PIK3CA—breast cancer	2.07e-07	2.91e-06	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—AKT1—breast cancer	1.69e-07	2.38e-06	CbGpPWpGaD
